Charles River Laboratories International (CRL) EBT (2009 - 2025)

Charles River Laboratories International (CRL) has reported EBT for 17 consecutive years, with -$294.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, EBT fell 35.66% year-over-year to -$294.1 million; the TTM figure through Dec 2025 stood at -$99.5 million (down 206.86% YoY), while the FY2025 annual figure was -$99.5 million, down 206.86% from the prior year.
• EBT came in at -$294.1 million for Q4 2025 at Charles River Laboratories International, down from $87.2 million in the prior quarter.
• The five-year high for EBT was $244.9 million in Q4 2022, with the low at -$294.1 million in Q4 2025.
• Average EBT over 5 years is $83.9 million, with a median of $116.3 million recorded in 2023.
• Across the five-year window, EBT soared 67.18% in 2022 and sank 203.87% in 2024, its largest moves.
• Year by year, EBT stood at $163.6 million in 2021, then jumped by 49.67% to $244.9 million in 2022, then decreased by 14.79% to $208.7 million in 2023, then tumbled by 203.87% to -$216.8 million in 2024, then plunged by 35.66% to -$294.1 million in 2025.
• According to Business Quant data, EBT over the past three periods registered -$294.1 million, $87.2 million, and $71.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.